Bispecific antibodies in cancer therapy

Current Opinion in Immunology

Volumn 11, Issue 5, 1999, Pages 558-562

  Segal, David M ^a   Weiner, George J ^b   Weiner, Louis M ^c  

^a Exp Immunol Br Natl Cancer I   (United States)

^b UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

^c FOX CHASE CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BISPECIFIC ANTIBODY;

CANCER; CANCER IMMUNOTHERAPY; CLINICAL TRIAL; EFFECTOR CELL; GENETIC ENGINEERING; HUMAN; MOLECULE; NONHUMAN; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; REVIEW; SIDE EFFECT; TUMOR CELL;

EID: 0032882746     PISSN: 09527915     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0952-7915(99)00015-1     Document Type: Review

References (43)

1. Karpovsky B, Titus JA, Stephany DA, Segal DM Production of target-specific effector cells using hetero-cross-linked aggregates containing anti-target cell and anti-Fc gamma receptor antibodies. J Exp Med. 160:1984;1686-1701.
2. Perez P, Hoffman RW, Shaw S, Bluestone JA, Segal DM Specific targeting of cytotoxic T cells by anti-T3 linked to anti-target cell antibody. Nature. 316:1985;354-356.
3. Staerz UD, Kanagawa O, Bevan MJ Hybrid antibodies can target sites for attack by T cells. Nature. 314:1985;628-631.
4. Noel PJ, Boise LH, Thompson CB Regulation of T cell activation by CD28 and CTLA4. Adv Exp Med Biol. 406:1996;209-217.
5. Wallace PK, Valone FH, Fanger MW Myeloid cell-targeted cytotoxicity of tumor cells. Fanger MW Bispecific Antibodies. 1995;43-76 RG Landes Company, Austin, Texas.
6. Deo YM, Sundarapandiyan K, Kelleher K, Wallace PK, Graziano RF Bispecific molecules directed to the Fc receptor for IgA (Fc alpha RI, CD89) and tumor antigens efficiently promote cell-mediated cytotoxicity of tumor targets in whole blood. J Immunol. 160:1998;1677-1686.
7. Van Spriel AB, Van Den Herik-Oudijk IE, Van Sorge NM, Vile HA, Van Strijp JA, Van de Winkel JG Effective phagocytosis and killing of Candida albicans via targeting FcgammaRI (CD64) or FcalphaRI (CD89) on neutrophils. J Infect Dis. 179:1999;661-669.
8. Segal DM, Vance BA, Sconocchia G Bispecific antibodies. Matzku S, Stahel RA Antibodies in Diagnosis and Therapy. Technologies, Mechanisms and Clinical Data. 1999;49-80 Harwood Academic Publishers, Amsterdam.
9. Cesano A, Visonneau S, Deaglio S, Malavasi F, Santoli D Role of, CD38 and its ligand in the regulation of MHC-nonrestricted cytotoxic T cells. J Immunol. 160:1998;1106-1115.
10. Lanier LL NK cell receptors. Annu Rev Immunol. 16:1998;359-393.
11. Yokoyama WM Natural killer cell receptors. Curr Opin Immunol. 10:1998;298-305.
12. Stahl PD, Ezekowitz RA The mannose receptor is a pattern recognition receptor involved in host defense. Curr Opin Immunol. 10:1998;50-55.
13. Franc NC, White K, Ezekowitz RA Phagocytosis and development: back to the future. Curr Opin Immunol. 11:1999;47-52.
14. Hoffmann JA, Kafatos FC, Janeway CA, Ezekowitz RA Phylogenetic perspectives in innate immunity. Science. 284:1999;1313-1318.
15. Medzhitov R, Preston-Hurlburt P, Janeway CA Jr. A human homologue of the Drosophila Toll protein signals activation of adaptive immunity. Nature. 388:1997;394-397.
16. Segal DM, Bast BJEG Production of bispecific antibodies. Coligan JE, Kruisbeek AM, Margulies DH, Shevach EM, Strober W Current Protocols in Immunology. 1995;2.13.1-2.13.16 John Wiley and Sons, Inc, New York.
17. 2 antibody containing thioether-linked Fab' gamma fragments. J Immunol. 139:1987;2367-2375.
18. Milstein C, Cuello AC Hybrid hybridomas and their use in immunohistochemistry. Nature. 305:1983;537-540.
19. Shalaby MR, Shepard HM, Presta L, Rodrigues ML, Beverley PCL, Feldmann M, Carter P Development of humanized bispecific antibodies reactive with cytotoxic lymphocytes and tumor cells overexpressing the HER2 protooncogene. J Exp Med. 175:1992;217-225.
20. Kostelny SA, Cole MS, Tso JY Formation of a bispecific antibody by the use of leucine zippers. J Immunol. 148:1992;1547-1553.
21. Bakacs T, Lee J, Moreno MB, Zacharchuk CM, Cole MS, Tso JY, Paik CH, Ward JM, Segal DM A bispecific antibody prolongs survival in mice bearing lung metastases of syngeneic mammary adenocarcinoma. Int Immunol. 7:1995;947-955.
22. Weiner GJ, Kostelny SA, Hillstrom JR, Cole MS, Link BK, Wang SL, Tso JY The role of T cell activation in anti-CD3 x antitumor bispecific antibody therapy. J Immunol. 152:1994;2385-2392.
23. Bird RE, Hardman KD, Jacobson JW, Johnson S, Kaufman BM, Lee SM, Lee T, Pope SH, Riordan GS, Whitlow M Single-chain antigen-binding proteins. Science. 242:1988;423-426.
24. Huston JS, Levinson D, Mudgett-Hunter M, Tai MS, Novotny J, Margolies MN, Ridge RJ, Bruccoleri RE, Haber E, Crea R, Oppermann H Protein engineering of antibody binding sites: recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in Escherichia coli. Proc Natl Acad Sci USA. 85:1988;5879-5883.
25. Pluckthun A, Pack P New protein engineering approaches to multivalent and bispecific antibody fragments. Immunotechnology. 3:1997;83-105.
26. Pack P, Pluckthun A Miniantibodies: use of amphipathic helices to produce functional, flexibly linked dimeric FV fragments with high avidity in Escherichia coli. Biochemistry. 31:1992;1579-1584.
27. Gruber M, Schodin BA, Wilson ER, Kranz DM Efficient tumor cell lysis mediated by a bispecific single chain antibody expressed in Escherichia coli. J Immunol. 152:1994;5368-5374.
28. Kurucz I, Titus JA, Jost CR, Jacobus CM, Segal DM Retargeting of CTL by an efficiently refolded bispecific single-chain Fv dimer produced in bacteria. J Immunol. 154:1995;4576-4582.
29. De Jonge J, Heirman C, De Veerman M, Van Meirvenne S, Moser M, Leo O, Thielemans K In vivo retargeting of T cell effector function by recombinant bispecific single chain Fv (anti-CD3 x anti-idiotype) induces long-term survival in the murine BCL1 lymphoma model. J Immunol. 161:1998;1454-1461. The first demonstration that an sc-bsAb is stable and can destroy tumors in vivo.
30. Holliger P, Prospero T, Winter G 'Diabodies': small bivalent and bispecific antibody fragments. Proc Natl Acad Sci USA. 90:1993;6444-6448.
31. Holliger P, Brissinck J, Williams RL, Thielemans K, Winter G Specific killing of lymphoma cells by cytotoxic T-cells mediated by a bispecific diabody. Protein Eng. 9:1996;299-305.
32. Adams GP, Schier R, McCall AM, Crawford RS, Wolf EJ, Weiner LM, Marks JD Prolonged in vivo tumour retention of a human diabody targeting the extracellular domain of human HER2/neu. Br J Cancer. 77:1998;1405-1412. The first demonstration that an antitumor diabody is stable and retains binding activity in vivo.
33. Canevari S, Stoter G, Arienti F, Bolis G, Colnaghi MI, Di Re EM, Eggermont AMM, Goey SH, Gratama JW, Lamers CHJet al. Regression of advanced ovarian carcinoma by intraperitoneal treatment with autologous T lymphocytes retargeted by a bispecific monoclonal antibody. J Natl Cancer Inst. 87:1995;1463-1469.
34. Lamers CH, Bolhuis RL, Warnaar SO, Stoter G, Gratama JW Local but no systemic immunomodulation by intraperitoneal treatment of advanced ovarian cancer with autologous T lymphocytes re-targeted by a bi-specific monoclonal antibody. Int J Cancer. 73:1997;211-219.
35. De Gast GC, Van Houten AA, Haagen IA, Klein S, De Weger RA, Van DIJK A, Phillips J, Clark M, Bast BJ Clinical experience with CD3 x CD19 bispecific antibodies in patients with B cell malignancies. J Hematother. 4:1995;433-437.
36. Kroesen BJ, Buter J, Sleijfer DT, Janssen RAJ, Van Der Graaf WTA, The TH, De Leij L, Mulder NH Phase I study of intravenously applied bispecific antibody in renal cell cancer patients receiving subcutaneous interleukin 2. Br J Cancer. 70:1994;652-661.
37. Tibben JG, Boerman OC, Massuger LF, Schijf CP, Claessens RA, Corstens FH Pharmacokinetics, biodistribution and biological effects of intravenously administered bispecific monoclonal antibody OC/TR F(ab')2 in ovarian carcinoma patients. Int J Cancer. 66:1996;477-483.
38. Link BK, Kostelny SA, Cole MS, Fusselman WP, Tso JY, Weiner GJ Anti-CD3-based bispecific antibody designed for therapy of human B-cell malignancy can induce T-cell activation by antigen-dependent and antigen-independent mechanisms. Int J Cancer. 77:1998;251-256.
39. Weiner LM, Holmes M, Richeson A, Godwin A, Adams GP, Hsieh-MA ST, Ring DB, Alpaugh RK Binding and cytotoxicity characteristics of the bispecific murine monoclonal antibody 2B1. J Immunol. 151:1993;2877-2886.
40. Weiner LM, Clark JI, Davey M, Li WS, Garcia De Palazzo I, Ring DB, Alpaugh RK Phase I trial of 2B1, a bispecific monoclonal antibody targeting c-erbB-2 and Fc gamma RIII. Cancer Res. 55:1995;4586-4593.
41. Valone FH, Kaufman PA, Guyre PM, Lewis LD, Memoli V, Deo Y, Graziano R, Fisher JL, Meyer L, Mrozek-Orlowski M Phase Ia/Ib trial of bispecific antibody MDX-210 in patients with advanced breast or ovarian cancer that overexpresses the proto-oncogene HER-2/neu. J Clin Oncol. 13:1995;2281-2292.
42. Curnow RT Clinical experience with CD64-directed immunotherapy. An overview. Cancer Immunol Immunother. 45:1997;210-215.
43. Posey JA, Raspet R, Verma U, Deo YM, Keller T, Marshall JL, Hodgson J, Mazumder A, Hawkins MJ A pilot trial of GM-CSF and MDX-H210 in patients with erbB-2-positive advanced malignancies. J Immunother. 22:1999;371-379.